Products and applications for diagnosis, treatment and prognosis prediction of pancreatic ductal adenocarcinoma
By developing biomarkers and inhibitors based on lncRNA-PATB1, the problems of early diagnosis and treatment of pancreatic ductal adenocarcinoma were solved, and the survival rate and prognosis of patients were significantly improved, and effective monitoring and prognosis of pancreatic ductal adenocarcinoma metastasis was achieved. predict.
Patent Information
- Application Number
- CN202410104467.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-03
- Filing Date
- 2024-01-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-01-25
AI Technical Summary
Pancreatic ductal adenocarcinoma has difficulty in early diagnosis, poor treatment effect and poor prognosis, and lack of effective biomarkers and therapeutic targets, resulting in high mortality and poor prognosis.
A biomarker based on long-chain non-coding RNA-PATB1 is developed to diagnose metastasis and prognostic prediction of pancreatic ductal adenocarcinoma and to provide inhibitors to reduce their expression levels for treatment and prognosis improvement.
By detecting the expression level of lncRNA-PATB1, early diagnosis and prognosis prediction of pancreatic ductal adenocarcinoma are achieved, and new therapeutic targets are found, which significantly improves the survival rate and prognosis of patients and reduces the risk of liver and peritoneal metastasis.
Smart Images

Figure CN117838867B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to products and applications thereof for diagnosis, treatment and prognosis prediction of pancreatic ductal adenocarcinoma. Background Art
[0002] Pancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis, with a 5-year survival rate of less than 9%.
[0003] Pancreatic ductal adenocarcinoma is the most common pathological type of pancreatic cancer, accounting for about 90% of pancreatic cancer cases. Radical surgical resection is currently the most effective way to treat pancreatic ductal adenocarcinoma, but due to its hidden early symptoms and lack of specific diagnostic methods, most patients have lost the opportunity for radical surgery when they seek medical treatment. Even with radical surgical treatment, the 5-year survival rate is still less than 20%. Therefore, pancreatic ductal adenocarcinoma has become the seventh leading cause of cancer-related death and may surpass breast cancer to become the third leading cause of cancer-related death in the future.
[0004] Although the overall incidence is not high, it still has a high mortality rate and poor prognosis due to its difficulty in early diagnosis and rapid progression. Tumor metastasis is an important factor affecting the prognosis of patients with pancreatic ductal adenocarcinoma. For patients who cannot undergo radical surgery, the median survival of patients with liver or peritoneal metastasis is significantly lower than that of patients without liver (6.2 months vs. 8.1 months) or peritoneal metastasis (5.2 months vs. 7.3 months). The occurrence of lymph node metastasis also significantly increases the postoperative recurrence rate of patients with pancreatic ductal adenocarcinoma (55% vs. 77%), which in turn leads to a significant decrease in the 5-year survival rate after surgery (27% vs. 11%).
[0005] Long non-coding RNA (lncRNA) is a general term for a class of RNAs with a length greater than 200 nucleotides and lacking the ability to encode proteins. lncRNA is abnormally expressed in a variety of tumors, including pancreatic ductal adenocarcinoma, and is involved in regulating the occurrence and development of tumors. lncRNAs mainly regulate tumors and their microenvironment by binding to proteins, RNA or DNA molecules, thereby mediating the occurrence of metastasis. However, the role and regulatory mechanism of lncRNAs in pancreatic ductal adenocarcinoma and its derived exosomes are less studied.
[0006] Therefore, it is important to find a biomarker based on long non-coding RNA that can effectively diagnose the proliferation, metastasis, and invasion of pancreatic ductal adenocarcinoma, to find new therapeutic targets based on long non-coding RNA, and to improve the prediction of patient prognosis based on long non-coding RNA. Summary of the invention
[0007] In order to overcome the deficiencies of the prior art, the main purpose of the present invention is to provide a biomarker lncRNA-PATB1, which can realize the diagnosis, treatment and prognosis prediction of pancreatic ductal adenocarcinoma.
[0008] To achieve the above object, the present invention provides the following technical solutions:
[0009] The first aspect of the present invention provides a product for diagnosing pancreatic ductal adenocarcinoma metastasis, the product comprising a reagent for detecting the expression level of lncRNA-PATB1;
[0010] The lncRNA-PATB1 is the RNA sequence shown in SEQ ID NO: 1.
[0011] The second aspect of the present invention provides a drug for treating pancreatic ductal adenocarcinoma, wherein the drug comprises an inhibitor for reducing the expression level of lncRNA-PATB1;
[0012] The lncRNA-PATB1 is the RNA sequence shown in SEQ ID NO: 1.
[0013] The third aspect of the present invention provides a product for predicting the prognosis of pancreatic ductal adenocarcinoma, the product comprising a reagent for detecting the expression level of lncRNA-PATB1;
[0014] The lncRNA-PATB1 is the RNA sequence shown in SEQ ID NO: 1.
[0015] A fourth aspect of the present invention provides any of the following applications:
[0016] (1) Use of an inhibitor of lncRNA-PATB1 or a pharmaceutical composition comprising the inhibitor in the preparation of a product for treating pancreatic ductal adenocarcinoma;
[0017] (2) Use of a reagent for detecting the expression level of lncRNA-PATB1 or a product comprising the reagent in the preparation of a tool for diagnosing pancreatic ductal adenocarcinoma metastasis / predicting the prognosis of pancreatic ductal adenocarcinoma;
[0018] (3) Application of lncRNA-PATB1 in constructing a system / device for diagnosing pancreatic ductal adenocarcinoma metastasis / predicting the prognosis of pancreatic ductal adenocarcinoma;
[0019] (4) Application of lncRNA-PATB1 in constructing a computer-readable storage medium for diagnosing pancreatic ductal adenocarcinoma metastasis / predicting the prognosis of pancreatic ductal adenocarcinoma.
[0020] Specifically, the lncRNA-PATB1 is the RNA sequence shown in SEQ ID NO: 1.
[0021] Specifically, the reagent is selected from an oligonucleotide probe that specifically recognizes the lncRNA-PATB1 gene, a primer that specifically amplifies the lncRNA-PATB1 gene, or a protein that specifically binds to the lncRNA-PATB1 gene.
[0022] Specifically, the product includes a chip, a kit or a nucleic acid membrane strip.
[0023] Specifically, the inhibitors include nucleic acid inhibitors and protein inhibitors.
[0024] Specifically, the system / device includes:
[0025] Acquisition unit: used to obtain the expression level of lncRNA-PATB1 in the sample;
[0026] Processing unit: According to the expression of lncRNA-PATB1, the diagnosis and metastasis / prognosis prediction results of pancreatic ductal adenocarcinoma are obtained.
[0027] Specifically, a computer program is stored on the computer-readable storage medium, and the computer program implements the aforementioned system / device when executed by a processor.
[0028] Beneficial effects of the present invention:
[0029] 1. The gene lncRNA-PATB1 is associated with the proliferation, metastasis and invasion of pancreatic ductal adenocarcinoma. lncRNA-PATB1 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.
[0030] 2. The gene lncRNA-PATB1 can serve as a new therapeutic target for pancreatic ductal adenocarcinoma.
[0031] 3. lncRNA-PATB1 is highly expressed in pancreatic ductal adenocarcinoma and is associated with poor prognosis of patients.
[0032] 4. The expression of exosomal lncRNA-PATB1 is correlated with lymph node metastasis and clinical stage.
[0033] 5. The expression of gene lncRNA-PATB1 can indicate the prognosis of pancreatic ductal adenocarcinoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1Figure 2 is a graph showing the correlation between the expression of lncRNA-PATB1 in pancreatic ductal adenocarcinoma and the poor prognosis of patients; A is a flowchart of high-throughput sequencing for screening lncRNAs associated with pancreatic ductal adenocarcinoma progression; B is a graph showing the expression of lncRNA-PATB1 in tumor and adjacent tissues of 192 patients with pancreatic ductal adenocarcinoma detected by qRT-PCR; CD is a graph showing the expression of lncRNA-PATB1 in pancreatic ductal adenocarcinoma tissues with different lymph node metastasis status and clinical stages detected by qRT-PCR; EF is a graph showing the effect of the expression level of lncRNA-PATB1 on the overall survival and disease-free survival of patients with pancreatic ductal adenocarcinoma; *p<0.05, **p<0.01.
[0035] Figure 2 Figure 2 is a graph showing that lncRNA-PATB1 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells; AD is a graph showing the effect of knocking down or overexpressing lncRNA-PATB1 on the proliferation ability of pancreatic ductal adenocarcinoma cells detected by CCK-8 experiment; EH is a graph showing the effect of knocking down or overexpressing lncRNA-PATB1 on the migration and invasion ability of pancreatic ductal adenocarcinoma cells detected by Transwell migration and invasion experiment, *p<0.05, **p<0.01.
[0036] Figure 3 Figure 1 shows animal experiments confirming that lncRNA-PATB1 promotes the metastasis of pancreatic ductal adenocarcinoma; AB shows the effect of lncRNA-PATB1 on pancreatic in situ tumor formation in mice detected by PET-CT; C shows the gross anatomy of the pancreatic in situ tumor model in mice; D shows the effect of lncRNA-PATB1 on liver metastasis in the pancreatic in situ tumor model in mice; E shows the effect of lncRNA-PATB1 on the survival time of mice with pancreatic in situ tumor formation; *p<0.05, **p<0.01.
[0037] Figure 4Figure 4 is a graph showing the activation of NF-κB pathway mediated by lncRNA-PATB1 recruiting hnRNPA1; AB is a graph showing proteins bound to lncRNA-PATB1 in RNA pμlldown experiments detected by silver staining and mass spectrometry; C is a graph showing the co-localization of lncRNA-PATB1 and hnRNPA1 in pancreatic cancer cells detected by FISH and immunofluorescence; D is a graph showing the binding of hnRNPA1 and lncRNA-PATB1 detected by RIP experiment; EF is a graph showing the effect of lncRNA-PATB1 overexpression on downstream target genes and pathways detected by qRT-PCR and Western blot; GH is a graph showing the effect of knocking down hnRNPA1 on IκBα expression detected by qRT-PCR; IJ is a graph showing the effect of knocking down hnRNPA1 on IκBα expression mediated by lncRNA-PATB1 overexpression detected by qRT-PCR; *p<0.05, **p<0.01.
[0038] Figure 5 Figure 2 is a graph showing the high expression of lncRNA-PATB1 in exosomes of pancreatic cancer cells; AC is a graph showing the identification of exosomes by transmission electron microscopy, NTA and western blot; D is a graph showing the expression of lncRNA-PATB1 in pancreatic cells and corresponding exosomes detected by qRT-PCR; EH is a graph showing the effect of silencing or overexpressing lncRNA-PATB1 on its expression in pancreatic cancer cells and corresponding exosomes detected by qRT-PCR; *p<0.05, **p<0.01.
[0039] Figure 6 Figure 2 shows that exosomal lncRNA-PATB1 promotes lymphatic endothelial regeneration; *p<0.05, **p<0.01.
[0040] Figure 7 Figure 2 is a diagram of the formation of DNA-RNA trimer between exosomal lncRNA-PATB1 and SOX18 promoter; AB is the expression of lncRNA-PATB1 in pancreatic cells and exosomes after downregulation of hnRNPA1; C is a diagram of the uptake of PKH67-labeled pancreatic cancer exosomes by lymphatic endothelial cells observed under confocal microscopy; DE is a diagram of the change in lncRNA-PATB1 expression in lymphatic endothelial cells after exosome induction; FG is a diagram of the effect of knockdown or overexpression of exosomal lncRNA-PATB1 on SOX18 expression in lymphatic endothelial cells detected by qRT-PCR; HI is a diagram of the binding of exosomal lncRNA-PATB1 to SOX18 promoter verified by ChIRP experiment; *p<0.05, **p<0.01.
[0041] Figure 8Figure 2 is a correlation diagram between exosomal lncRNA-PATB1 and lymph node metastasis of pancreatic ductal adenocarcinoma; A is the expression diagram of lncRNA-PATB1 in serum exosomes of 92 pancreatic ductal adenocarcinoma patients and 92 normal subjects detected by qRT-PCR; BC is the expression diagram of lncRNA-PATB1 in serum exosomes of pancreatic ductal adenocarcinoma patients with different lymph node metastasis status and clinical stages detected by qRT-PCR; *p<0.05, **p<0.01.
[0042] Fig. 9 Figure 2 is a graph showing the correlation between high expression of exosomal lncRNA-PATB1 and poor prognosis of patients; AB is a graph showing the effect of the expression level of lncRNA-PATB1 in serum exosomes of patients with pancreatic ductal adenocarcinoma on their overall survival and disease-free survival; C is a graph showing the effect of the expression level of lncRNA-PATB1 in serum exosomes of patients on the overall survival of patients with pancreatic ductal adenocarcinoma with lymph node metastasis; *p<0.05, **p<0.01. DETAILED DESCRIPTION
[0043] In order to better understand the present invention, the present invention is further described below in conjunction with specific examples, wherein the terms used in the examples are for describing specific embodiments and do not constitute limitations on the scope of protection of the present invention.
[0044] 1. Materials and methods of the embodiments
[0045] 1. Tissue Specimens
[0046] The present invention collected a total of 192 pairs of pancreatic ductal adenocarcinoma tissues and adjacent tissues that underwent surgical treatment at Sun Yat-sen Memorial Hospital of Sun Yat-sen University from 2013 to 2018. In addition, blood specimens were collected from 92 pancreatic patients and 92 healthy subjects. The tissue specimens were all diagnosed as pancreatic ductal adenocarcinoma by pathologists. All patients signed informed consent forms before surgical resection of the tumor. All specimen acquisition has been approved by the hospital ethics committee. All tissue specimens were quickly frozen in liquid nitrogen after being taken out and stored in a -80 degree refrigerator. After the blood specimens were collected, they were centrifuged at 2000rpm for 15 minutes, and the upper serum samples were collected and stored in a -80 degree refrigerator.
[0047] 2. Cell lines and culture
[0048] The pancreatic ductal adenocarcinoma cell lines used in the present invention: AsPC-1, BxPC-3, PANC1 and Capan-2, bladder cancer cell lines: UM-UC-3, 5637, T24, human normal pancreatic ductal epithelial cell line HPDE and human normal bladder epithelial cell line Sv-HUC were all purchased from the American Tissue Type Culture collection (ATCC). In this experiment, PANC-1, Capan-2 and UM-UC-3 cell lines were cultured in DMEM medium (Gibco, USA) containing 10% fetal bovine serum, AsPC-1, BxPC-3, 5637, T24 and HPDE cell lines were cultured in RPMI 1640 medium (Gibco, USA) containing 10% fetal bovine serum, and Sv-HUC cell line was cultured in F12K medium (Gibco, USA) containing 10% fetal bovine serum. Human lymphatic endothelial cells (HLECs) were purchased from ScienCell Research Laboratories (USA) and cultured in ECM medium (ScienCell, USA) containing 5% fetal bovine serum. All cells were cultured in an incubator at 37°C and 5% carbon dioxide.
[0049] 3. Antibodies
[0050] Table 1 Antibodies used in the experiments
[0051]
[0052]
[0053] 4. Experimental Instruments
[0054] Table 2 Instruments used in the experiment
[0055]
[0056]
[0057] 5. RNA interference and cell transfection
[0058] Pancreatic ductal adenocarcinoma cells were routinely cultured and the cells were digested with trypsin at a rate of 1.5 × 10 5Cells were inoculated into six-well plates, 2 ml of complete medium was added, and the cells were placed in an incubator overnight until the cell confluence reached 50%-60%. After the siRNA or plasmid synthesized by Shanghai GenePharma (Shanghai) was dissolved in DEPC water, 5 μl of siRNA or 5 μg of plasmid was taken from each well and added to 250 μl of opti-MEN medium. When transfecting the plasmid, 5 μl of P3000 (Life Technologies, USA) reagent was added. 5 μl / well of transfection reagent Lipofectamine 3000 (Life Technologies, USA) was diluted in 250 μl of opti-MEN medium. The siRNA and Lipofectamine 3000 diluted solutions were mixed, allowed to stand at room temperature for 20 minutes, and then added to the cells to be transfected. The complete medium was replaced 12 hours after transfection. The transfection efficiency was measured after 72 hours.
[0059] 6. Construction of Lentivirus Stable Transfection Cells
[0060] After pancreatic ductal adenocarcinoma cells were inoculated into 10 cm culture dishes, they were cultured routinely until the cell confluence reached 50%-60%. 7.5 μg PAX2, 2.5 μg MD2 and 10 μg lentiviral plasmid were added to 2.5 ml OptiMEN medium, and 60 μl Lipofectamine 3000 was added to another 2.5 ml Opti-MEN medium. The above two solutions were mixed and allowed to stand at room temperature for 30 minutes. The mixed solution was evenly added to the culture dish in which the cells were cultured and placed in an incubator for 72 hours. The cell supernatant was collected and centrifuged at 1000 rpm for 5 minutes at 4°C, and the supernatant was stored in a refrigerator at -80 degrees. Pancreatic ductal adenocarcinoma cells were inoculated into 6-well plates. Cultured until the cell confluence reached 80%. Thaw the lentiviral supernatant stored at -80 degrees, take 1 ml and mix it with an equal amount of complete culture medium, and add Polybrene solution. The mixed solution was added to a six-well plate and cultured in an incubator. After 48 hours, the cells were selected with puromycin for 1 week to obtain a stably transfected pancreatic ductal adenocarcinoma cell line.
[0061] 7. RNA Extraction and qRT-PCR
[0062] After the cell culture medium in the six-well plate is completely aspirated, the cells are washed twice with pre-cooled PBS, 1 ml of Trizol solution is added, and the cells are lysed at room temperature for 10 minutes. The cell lysate is transferred to an enzyme-free EP tube, 200 μl of chloroform reagent is added, and the mixture is shaken vigorously for 10 seconds. After standing at room temperature for 5 minutes, it is centrifuged at 4°C and 12000 rpm for 15 minutes. After centrifugation, the upper liquid phase is carefully aspirated to a new EP tube, an equal volume of isopropanol is added, the mixture is inverted and mixed, and after standing at room temperature for 5 minutes, it is centrifuged at 4°C and 12000 rpm for 10 minutes. Carefully aspirate the supernatant to avoid aspirating the precipitate. Add 1 ml of 75% ethanol to the EP tube and centrifuge at 4°C and 7500 rpm for 5 minutes. Discard the supernatant, dry the precipitate at room temperature, add 10 μl of DEPC water to the EP tube to dissolve the precipitate, and use Nanodrop to measure the RNA concentration.
[0063] Take 500ng total RNA, mix with 2μl 5× PrimeScript RT Master Mix (Takara, Japan) to prepare a 10μl system and reverse transcribe into cDNA. After diluting 10 times, take 1μl cDNA, add primers and 5μl TBGreen II (Takara, Japan) for qRT-PCR analysis. The gene expression difference was calculated by comparative Ct relative quantitative method. GAPDH was used as the internal reference, and at least 3 secondary wells were set for each sample. The primers used in the present invention are listed as follows:
[0064] Table 3 Primers used in the experiment
[0065] name Upstream primer Downstream primer lncRNA-PATB1 TCTCATCCCGTGTCATGTGCC GTTTCAGGTCTCCATGCCAGTG GAPDH ATCACCATCTTCCAGGAGCGA CCTTCTCCATGGTGGTGAAGAC U1 GGGAGATACCATGATCACGAAGGT CCACAAATTATGCAGTCGAGTTTC IL-6 ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG IκBα TGGTCAGTGCCTTTTCTTCAT GGAGTACGAGCAGATGGTCAA E2F1 GGACCTTCGTAGCATTGCAGAC TCAGGGCACAGGAAAACATCG MDM2 GACGTAGAGGCGAGGATTCC GCTGGGAGTGCCGTATGTC STAT3 CAGCAGCTTGACACACGGTA AAACACCAAAGTGGCATGTGA TGF-β TGCCTTCAGCAGAGTGAAGA GTCTTGGTTCTCAGCTTGGG LNMAT2 GGTTCAGTTGGGCAAAAGGC TCATTCAGTCACAGGGTGGC SOX18 CTTCATGGTGTGGGCAAAGG CCGGTACTTGTAGTTGGGGT PAI-1 ACCGCAACGTGGTTTTCTCA TTGAATCCCATAGCTGCTTG IFGBP3 AGAGCACAGATACCCAGAAC GGTGATTCAGTGTGTCTTCC
[0066] 8. Western Blot Analysis
[0067] (1) Glue preparation: Fix the glass plate tightly on the glue preparation rack, prepare separation gel as needed, carefully pour separation gel from one corner, pour in anhydrous ethanol to seal, press the glue, let it stand at room temperature for 30 minutes, and then pour out the anhydrous ethanol. Prepare concentrated gel as needed, pour it into the glass plate, insert a comb, and let it stand at room temperature for 30 minutes to solidify.
[0068] (2) Sample loading: Insert the prepared gel into the electrophoresis tank, add the newly prepared electrophoresis solution into the inner tank. Insert the prepared gel into the electrophoresis tank, gently pull out the comb, load the sample, and add 3μl protein marker.
[0069] (3) Electrophoresis: Add electrophoresis solution to the outer tank, connect the tank to the power supply, adjust the voltage to 65 V, and when the bromophenol blue indicator band runs to the separation gel, adjust the voltage to 100 V and continue electrophoresis until the marker runs to the bottom of the gel, then stop electrophoresis.
[0070] (4) Electrotransfer: Cut the PVDF membrane and soak it in methanol for 10 minutes to activate it. Remove the membrane, gently lift up the short glass plate, carefully cut off the concentrated gel and the unnecessary lower part, soak the electrotransfer clip in the electrotransfer solution, clamp it in the order of white surface, sponge pad, filter paper, membrane, gel, sponge pad, black surface, and put it in the electrotransfer tank. Add electrotransfer solution and put the electrotransfer tank in a large foam box filled with ice. Connect a constant current of 250mA for 90 minutes. Turn off the power and remove the membrane.
[0071] (5) Blocking: The membrane was placed in BSA blocking solution (5% BSA solution, prepared with TBST) and shaken slowly at room temperature for 1 hour.
[0072] (6) Primary antibody incubation: Discard the blocking solution, cut the membrane into strips as needed, place in the primary antibody, and shake at 4°C overnight.
[0073] (7) Secondary antibody incubation: On the second day, remove the membrane from the primary antibody and wash it with TBST for 3 times, 10 minutes each. Place the membrane in the secondary antibody and shake it slowly for 1 hour. Then wash it with TBST for 3 times, 10 minutes each.
[0074] (8) Exposure: Prepare the luminescent solution using the ECL luminescent solution kit (Millipore, USA), in which the AB solution is mixed in a ratio of 1:1. Add the luminescent solution to the membrane in a darkroom, cover it with X-ray film for exposure, use different pressing times according to different luminescent brightness, and then put it into the film processor for development.
[0075] 9. Isolation and purification of exosomes
[0076] The extraction of exosomes from the cell culture supernatant was performed by ultracentrifugation, while the extraction of exosomes from the patient's serum was performed using an exosome extraction kit (Thermo Fisher, USA). The ultracentrifugation method was as follows: After collecting the cell culture supernatant, centrifuge at 2000xg for 15 minutes to remove cells and cell debris in the culture medium. The supernatant was further centrifuged at 4°C, 10000xg for 30 minutes to remove larger vesicles. The supernatant was transferred to a new centrifuge tube and centrifuged at 4°C, 120000xg for 70 minutes, then the supernatant was discarded, PBS was added and centrifuged at 4°C, 120000xg for 70 minutes to wash the exosomes, and the sediment at the bottom of the centrifuge tube was naturally air-dried after discarding the supernatant. An appropriate amount of PBS was taken to resuspend the suspension to obtain the exosome suspension, which was stored in a -80°C refrigerator for further experimental use.
[0077] 10. Electron microscopy identification of exosomes
[0078] After the exosomes were diluted 10 times with PBS, they were added to the electron microscope grid (PolySciences, USA) and allowed to settle for 30 minutes. After the liquid was removed with filter paper, they were fixed with 2% glutaraldehyde (SigmaAldrich, USA) for 10 minutes. The grid was then washed with PBS 5 times, stained with 2% uranyl acetate (SigmaAldrich, USA) for 1 minute, washed with PBS, dried in a fume hood, and observed and photographed under a transmission electron microscope (Hitachi, Japan).
[0079] 11. Cell proliferation assay
[0080] The present invention uses CCK-8 assay to evaluate the proliferation ability of cells. 3 Pancreatic ductal adenocarcinoma cells were seeded in 96-well plates 24 hours after transfection and placed in a 37°C 5% CO 2 Culture in an incubator. At the corresponding time points (24 hours, 48 hours, 72 hours, and 96 hours), take out the 96-well plate, add 10 μl of CCK-8 reagent, and incubate in an incubator for 2 hours. Use an enzyme marker to measure and record the absorbance value at a wavelength of 450 nm.
[0081] 12. Cell invasion and migration assay
[0082] The present invention uses the Transwell assay to evaluate the migration and invasion ability of cells. Pancreatic ductal adenocarcinoma cells were digested from the six-well plate 48 hours after transfection, centrifuged, resuspended in a culture medium without fetal bovine serum, and counted. 2×10 5 Cells / well were added with serum-free medium until the cell suspension was 200 μl, which was then inoculated into the upper chamber of the Transwell chamber without or with pre-laid matrix gel. 700 μl of complete medium was added to the lower chamber and the chamber was placed at 37°C with 5% CO. 2 Culture in an incubator. After about 16 hours, remove the chamber, remove the culture medium, and fix the cells with methanol for 15 minutes. After washing the residual methanol with PBS, stain with 0.1% crystal violet stain for 15 minutes. Wash away the residual dye with PBS, and gently wipe the cells inside the chamber with a cotton swab. Observe under a microscope, take pictures, record, and compare the cell migration between different experimental groups.
[0083] 13. Lymphangiogenesis Assay
[0084] The present invention uses a lymphangiogenesis experiment to evaluate the proliferation capacity of lymphatic endothelial cells. The lymphatic endothelial cells were digested with trypsin, centrifuged, and resuspended in ECM medium without added serum and growth factors, and then counted. 1×10 5Cells / well were seeded in a 2-well plate pre-coated with matrix gel and PBS or pancreatic cancer exosomes from different treatment groups were added. About 12 hours later, the lymphatic vessel formation was observed under a microscope, photographed, and compared between different experimental groups.
[0085] 14. Nude mouse orthotopic tumor model
[0086] The 4-5 week old nude mice used in the experiment were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd. and were raised in the Animal Experiment Center of the School of Medicine of Sun Yat-sen University. After being anesthetized with 4% chloral hydrate (0.1 ml / g), the nude mice were placed in the right side recumbent position, the skin on the left side of the nude mice was cut open, and the spleen was turned over to fully expose the pancreas. 5×10 6 Pancreatic ductal adenocarcinoma cells were injected into the pancreas from the pancreatic tail to the head, and the skin of the nude mice was sutured with 5-0 sutures. The weight of the nude mice was recorded every 3 days. PET-CT (Siemens, Germany) was performed 4 weeks later to detect the in situ tumor formation and liver metastasis of the nude mice. The in situ tumor tissues of the nude mice were dissected, and the size of the tumor tissues between different experimental groups was recorded.
[0087] 15. Nude Mouse Popliteal Lymph Node Metastasis Model
[0088] The experiment used 4-5 week old nude mice. 6 Fluorescently labeled tumor cells were injected into the right foot pad of nude mice to establish a nude mouse popliteal lymph node metastasis model. 3 PBS and exosomes from different treatment groups were injected intratumorally. The body weight of nude mice was recorded every 3 days, and live imaging was performed every week to detect the metastasis of popliteal lymph nodes of nude mice. The nude mice were observed until death, and the foot pad tumors and popliteal lymph node tissues of nude mice were dissected. The size of lymph nodes between different experimental groups was recorded, and the tumor and lymph node tissues were soaked in formalin for further experimental analysis.
[0089] 16. RNA pμlldown
[0090] This experiment was divided into three parts: in vitro transcription, biotin probe labeling of RNA and RNA Pμlldown. All steps were carried out according to the manufacturer's instructions of the corresponding kit.
[0091] (1) In vitro transcription: First, thaw the reagents and place the NTP / CAP on ice. Keep the reaction buffer at room temperature. Mix the reagents according to the standard system ratio and incubate at 37°C for 2 hours. Add DNase and incubate at 37°C for 15 minutes to remove the influence of template DNA. Extract the target RNA using an RNA purification kit and store it in a -80°C refrigerator for use in the next step.
[0092] (2) Biotin probe labeling RNA: Place PEG and DMSO reagents at room temperature and dissolve the remaining reagents on ice. Place the target and control RNA at 85°C for 5 minutes and then on ice for 5 minutes to fully denature the RNA. Prepare the mixture according to the standard system and incubate at 16°C overnight. Extract the labeled RNA with phenol chloroform for further use.
[0093] (3) RNA Pμlldown: After collecting pancreatic ductal adenocarcinoma cells, add cell lysis buffer to fully lyse the cells, and centrifuge at 3000 rpm for 10 minutes at 4°C to obtain the cell lysate supernatant. Prepare magnetic beads for the experiment, mix them with the labeled RNA, and rotate and incubate at room temperature for 20 minutes to allow the magnetic beads and RNA to be fully mixed. Add the supernatant of the cell lysate to the treated magnetic beads and add ribonuclease inhibitors, and rotate and incubate at 4°C for 2 hours. Remove the supernatant through a magnetic stand, and add pre-cooled 0.1% SDS solution and protein loading buffer to resuspend the magnetic beads. Boil at 98°C for 10 minutes, remove the magnetic beads, and transfer the supernatant to a new EP tube. Further analyze the experimental results by silver staining and subsequent mass spectrometry or Western blot.
[0094] 17. RNA binding protein immunoprecipitation (RIP) experiment
[0095] This experiment used the RIP kit from Merck Millipore. All experimental steps were performed according to the instructions provided by the manufacturer. First, prepare and collect 1×10 7Pancreatic ductal adenocarcinoma cells per group. They were placed in 100 μl of cell lysis buffer containing 0.5 μl of protease inhibitor and 0.25 μl of ribonuclease inhibitor and fully lysed on ice for 5 minutes. The obtained lysate of about 100 μl was stored in a -80°C refrigerator overnight. Immunoprecipitation magnetic beads were prepared by taking 50 μl of magnetic bead suspension in a 1.5 ml centrifuge tube, washing it twice with RIP washing buffer, adding 5 μl of the target antibody and incubating it at room temperature for 30 minutes. The cell lysate was quickly thawed and centrifuged at 4°C, 14000 rpm for 10 minutes, 10 μl of supernatant was taken and marked as input, and the rest of the supernatant was added to RIP immunoprecipitation buffer containing magnetic bead antibody complex and incubated at 4°C overnight. After washing the immunoprecipitate with RIP washing buffer, proteinase K buffer was added, and the input was also incubated with proteinase K buffer to digest the protein. Take the supernatant in a new centrifuge tube, add 400 μL of phenol: chloroform: isoamyl alcohol (25:24:1), shake vigorously for 15 seconds, and centrifuge at 14000 rpm for 10 minutes at room temperature. Take the aqueous phase after centrifugation, add anhydrous ethanol and precipitation enhancer, and store it at -80°C overnight to fully precipitate RNA. Centrifuge and discard the supernatant, air-dry the precipitate, dissolve it in enzyme-free water, reverse transcribe it, and further analyze the experimental results by qRT-PCR.
[0096] 18. Chromatin Isolation and RNA Purification (ChIRP) Experiment
[0097] This experiment used the ChIRP kit from Merck Millipore. All experimental steps were performed according to the instructions provided by the manufacturer. First, 2×10 7 Pancreatic ductal adenocarcinoma cells were fixed with 20 ml 1% glutaraldehyde at room temperature for 10 minutes, and then unreacted glutaraldehyde was neutralized with 2 ml glycine. The cells were centrifuged at 4 ° C and 1000 rpm for 5 minutes, and the supernatant was discarded. The cells were washed three times with PBS. According to the quality of the precipitate, 1 ml / 100 g lysis buffer was added to fully resuspend the precipitate and then the DNA fragments were fragmented under ultrasound. 10 μl of the precipitate was taken out as DNA input and 10 μl as RNA input. The probes were added to the remaining experimental samples respectively and hybridized at 37 ° C for 4 hours. Then 100 μl of magnetic bead suspension was added and incubated at 37 ° C for 30 minutes. After washing 5 times with washing buffer, DNA eluent, ribonuclease A and proteinase K were added, mixed thoroughly, incubated at 55 ° C for 1 hour, added to the adsorption column, separated and purified DNA, and the experimental results were further analyzed by qRT-PCR.
[0098] 19. Chromatin immunoprecipitation (ChIP) assay
[0099] This experiment used the ChIP kit from Merck Millipore. All experimental steps were performed according to the instructions provided by the manufacturer. First, 1×10 7 Pancreatic ductal adenocarcinoma cells were added with 37% formaldehyde to a final concentration of 1%. After fixation at room temperature for 10 minutes, unreacted formaldehyde was neutralized with one-tenth volume of glycine. Centrifuge at 4°C, 1000rpm for 5 minutes and discard the supernatant, wash three times with PBS. Add 1ml lysis buffer to fully resuspend the precipitate and fragment the DNA fragments under ultrasound. Take 100μl of lysis product and add 900μl dilution buffer, take 10μl and mark it as input, and add the rest of the antibody and incubate at 4°C overnight. Then add magnetic beads and incubate at 4°C for 1 hour, add low salt washing solution, high salt washing solution, LiCl washing solution and TE solution to wash, add 100ul elution solution to elute twice, and add 8ul NaCl at 65°C to decrosslink. After the crosslinking is completed, add ribonuclease A and proteinase K to treat, add to the adsorption column to separate and purify DNA, and further analyze the experimental results by qRT-PCR.
[0100] 20. Dual luciferase reporter gene assay
[0101] This experiment was conducted using the experimental reagents and procedures of Promega. First, the target gene was constructed into the luciferase plasmid, and the plasmid was transfected into the cells. After 36 hours of transfection, the culture medium in the six-well plate was discarded and washed 3 times with PBS. 500μl of lysis solution was added to each well, and it was placed in a shaker and slowly shaken for 15 minutes to fully lyse the cells. 20μl of the above cell lysate was added to the 96-well plate and 100μl of the pre-prepared LuciferaseAssay ReagentII reagent was added to detect the reaction intensity of luciferase after 2 seconds. Then 100μl of the pre-prepared Stop&GloReagent reagent was added to detect the reaction intensity of Renilla luciferase after 2 seconds, and the values of the two were recorded and compared.
[0102] 21.FISH and Immunofluorescence
[0103] (1) In situ hybridization: 5×10 4 Cells were inoculated in confocal microplates and cultured overnight. 1 ml of 4% paraformaldehyde was added for fixation, 0.1% TritonX-100 was added for membrane permeabilization, and probes, 2×SSC, 10% formamide, and 10% dextran were added and hybridized overnight at 37°C. Finally, the cell nuclei were stained with DAPI, and the images were observed and recorded under a confocal microscope.
[0104] (2) Immunofluorescence: 5×10 4The cells were seeded in a confocal dish, fixed with 1 ml of 4% paraformaldehyde after overnight culture, and permeabilized with 0.1% TritonX-100, washed twice with PBST, and blocked with 50 μl of 1% PBS. Then, the cells were mixed with the primary antibody and incubated at 4°C overnight, followed by incubation with the secondary antibody at room temperature for 30 minutes, and finally, the cell nuclei were stained with DAPI, and the images were observed and recorded under a confocal microscope.
[0105] 22. Exosome Uptake Experiment
[0106] In this experiment, the PKH67 fluorescent labeling kit (SigmaAldrich, USA) was used to stain exosomes. After isolating exosomes from the cell supernatant, PKH67 was added for staining for 2 minutes, and then 1% PSA was added to terminate the staining. PKH67-labeled exosomes were separated by ultracentrifugation and resuspended in culture medium supplemented with 10% exosome-free fetal bovine serum. After incubating PKH67-labeled exosomes with lymphatic endothelial cells for 12 hours, the cells were washed twice with PBS and fixed with 4% paraformaldehyde. Finally, the cell nuclei were stained with DAPI, and the images were observed and recorded under a confocal microscope.
[0107] 23. Statistical analysis
[0108] All statistical analyses in this invention were performed using SPSS 22.0 software, where p < 0.05 was considered statistically significant. All experiments were repeated three times, and quantitative data were expressed as mean ± standard deviation. For statistical analysis of data, Mann-Whitney U test was used for analysis of non-normally distributed data, t-test or analysis of variance was used for parametric variables, and χ test was used for non-parametric variables. 2 The overall survival and disease-free survival of patients were evaluated by Kaplan-Meier method, and the factors affecting the prognosis of patients' survival were analyzed by Cox regression analysis.
[0109] 2. Experimental results of the embodiment
[0110] 1. Screening and identification of lncRNA-PATB1
[0111] The present invention screened for differentially expressed lncRNA-PATB1 by performing gene chip analysis on 8 cases of pancreatic ductal adenocarcinoma tissues and 4 cases of normal pancreatic tissues. Among them, 26 lncRNAs were upregulated more than 5 times in pancreatic ductal adenocarcinoma tissues ( Figure 1 A). The top five lncRNAs were selected based on the difference fold, and their expression was further expanded to 192 tissue samples from patients with pancreatic ductal adenocarcinoma. The results showed that only lncRNA-PATB1 was expressed higher in pancreatic ductal adenocarcinoma tissue than in adjacent tissues ( Figure 1B). Therefore, lncRNA-PATB1 was selected for further study.
[0112] 2. lncRNA-PATB1 is associated with metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma
[0113] The present invention further detected the relationship between the expression of lncRNA-PATB1 and the clinical pathological characteristics of patients with pancreatic ductal adenocarcinoma and found that the expression of lncRNA-PATB1 was positively correlated with the lymph node metastasis and TNM stage of pancreatic ductal adenocarcinoma ( Figure 1 CD, Table 4). In addition, follow-up results showed that overexpression of lncRNA-PATB1 was positively correlated with poor prognosis in patients with pancreatic ductal adenocarcinoma ( Figure 1 EF). Univariate and multivariate analysis showed that the expression of lncRNA-PATB1 was an independent prognostic factor affecting the survival of patients with pancreatic ductal adenocarcinoma (Table 5). The above results suggest that lncRNA-PATB1 is associated with metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma.
[0114] Table 4 Relationship between LncRNA-PATB1 expression and clinical characteristics of patients with pancreatic ductal adenocarcinoma
[0115]
[0116]
[0117] Note: a Chi-square test, *p<0.05, **p<0.01.
[0118] Table 5 Univariate and multivariate analysis of factors affecting overall survival (OS) in patients with pancreatic ductal adenocarcinoma (n = 192)
[0119]
[0120] Note: *p<0.05, **p<0.01
[0121] 3. In vitro experiments confirmed that lncRNA-PATB1 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells
[0122] The present invention further explored the effect of lncRNA-PATB1 on the function of pancreatic ductal adenocarcinoma cells through in vitro experiments. CCK-8 experiments showed that downregulating the expression of lncRNA-PATB1 significantly inhibited the proliferation activity of pancreatic ductal adenocarcinoma cells, while overexpression of lncRNA-PATB1 enhanced the proliferation activity of pancreatic ductal adenocarcinoma cells, indicating that lncRNA-PATB1 promotes the proliferation of pancreatic ductal adenocarcinoma ( Figure 2AD). In addition, the present invention confirmed through Transwell migration and invasion experiments that after knocking down lncRNA-PATB1, the migration and invasion abilities of pancreatic ductal adenocarcinoma cells were significantly reduced ( Figure 2 EH). The above in vitro experimental results show that lncRNA-PATB1 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.
[0123] 4. In vivo experiments confirmed that lncRNA-PATB1 promotes invasion and metastasis of pancreatic ductal adenocarcinoma
[0124] The present invention further studies the effect of lncRNA-PATB1 on the progression of pancreatic ductal adenocarcinoma by constructing an in situ model of pancreatic ductal adenocarcinoma. The present invention divided 20 nude mice into two groups, 10 in each group, and injected PANC-1 cells stably transfected with sh-NC or sh-PATB1#1 lentiviral plasmids into the pancreas of nude mice. PET-CT analysis showed that 18F-deoxyglucose ( 18 The uptake rate of 247 FDG was significantly reduced, indicating that knocking down the expression of lncRNA-PATB1 inhibited the growth of pancreatic ductal adenocarcinoma ( Figure 3 AB). Compared with the sh-NC group, the tumor volume of the sh-PATB1#1 group was reduced ( Figure 3 C). In addition, lncRNA-PATB1 silencing reduced the incidence of liver metastasis in tumor-bearing mice, suggesting that lncRNA-PATB1 promotes the metastasis of pancreatic ductal adenocarcinoma ( Figure 3 D). Survival analysis showed that downregulating the expression of lncRNA-PATB1 prolonged the survival time of mice ( Figure 3 E) The experimental results suggest that lncRNA-PATB1 promotes the invasion and metastasis of pancreatic ductal adenocarcinoma in vivo.
[0125] 5. LncRNA-PATB1 binds to hnRNPA1 to mediate NF-kB pathway activation
[0126] The interaction between RNA and protein is the main form of lncRNA function. Therefore, the present invention further identifies proteins that interact with lncRNP-PATB1 in pancreatic ductal adenocarcinoma. RNA pμlldown and subsequent silver staining experiments revealed that after coprecipitation, there was an obvious differential band at 35-55kDa, and mass spectrometry confirmed that it was hnRNPA1 protein ( Figure 4 AB). FISH combined with immunofluorescence staining showed that lncRNA-PATB1 and hnRNPA1 were co-localized in the nucleus and cytoplasm of pancreatic ductal adenocarcinoma cells ( Figure 4C). RIP experiments further confirmed that hnRNPA1 can specifically enrich lncRNP-PATB1, suggesting that LncRNA-PATB1 directly binds to hnRNPA1 ( Figure 4 D).
[0127] Previous studies have reported that hnRNPA1 is involved in regulating the activation of the NF-κB signaling pathway in pancreatic ductal adenocarcinoma. Therefore, the present invention further clarifies whether lncRNA-PATB1 mediates the activation of the NFκB signaling pathway after binding to hnRNPA1. The results confirmed that overexpression of lncRNA-PATB1 significantly downregulated the expression of IκBα and activated the NF-κB signaling pathway ( Figure 4 EF), while knockdown of hnRNPA1 reversed the effect of lncRNA-PATB1 on the NF-κB signaling pathway ( Figure 4 The above results suggest that lncRNA-PATB1 downregulates the expression of IκBα by binding to hnRNPA1 and thus activates the NF-κB signaling pathway.
[0128] 6. Identification of lncRNA-PATB1 as highly expressed in exosomes of pancreatic ductal adenocarcinoma
[0129] The present invention uses ultracentrifugation to separate and purify exosomes from the culture supernatant of pancreatic ductal adenocarcinoma and normal pancreatic ductal epithelial cells, and identifies them as cup-shaped exosome particles with a size of 30-150 nm by transmission electron microscopy and nanoparticle tracing analysis. Figure 5 AB). Western blot analysis confirmed that it highly expressed exosome marker proteins CD9 and CD63 ( Figure 5 C). Further qRT-PCR detection revealed that the expression of lncRNA-PATB1 in exosomes derived from pancreatic ductal adenocarcinoma cell lines was significantly higher than that in exosomes derived from normal pancreatic ductal epithelial cells ( Figure 5 D). The present invention found that the abundance of lncRNA-PATB1 in exosomes derived from pancreatic ductal adenocarcinoma cells was higher than that in cells, suggesting that exosome-mediated lncRNA-PATB1 may play an important role in the progression of pancreatic ductal adenocarcinoma ( Figure 5 D). Silencing the expression of lncRNA-PATB1 in pancreatic ductal adenocarcinoma cells significantly reduced the expression of lncRNA-PATB1 in pancreatic ductal adenocarcinoma exosomes, while the opposite was true for lncRNA-PATB1 overexpressed in cells, suggesting that the expression of exosomal lncRNA-PATB1 is affected by the expression of intracellular lncRNA-PATB1 ( Figure 5 EH). The results suggest that lncRNA-PATB1 is highly expressed in exosomes of pancreatic ductal adenocarcinoma.
[0130] 7. Preliminary functions of exosomal lncRNA-PATB1
[0131] Lymphatic endothelial regeneration is an important rate-limiting step in the process of tumor lymph node metastasis. Tumor-derived exosomes can promote lymphatic metastasis by mediating lymphatic endothelial regeneration. Therefore, the present invention further explores whether exosomal lncRNA-PATB1 can promote lymphatic endothelial regeneration. Tube formation and Transwell experiments showed that compared with the control group, downregulating the expression of lncRNA-PATB1 in exosomes derived from pancreatic ductal adenocarcinoma cells inhibited the tube formation and migration of lymphatic endothelial cells ( Figure 6 AC). Similarly, after co-incubation with pancreatic ductal adenocarcinoma exosomes overexpressing lncRNA-PATB1, the tube-forming and migration abilities of lymphatic endothelial cells were significantly enhanced ( Figure 6 DF). The above results indicate that exosomal lncRNA-PATB1 derived from pancreatic ductal adenocarcinoma induces lymphatic vessel endothelial regeneration.
[0132] 8. Preliminary study on the mechanism of exosomal lncRNA-PATB1 promoting lymphangiogenesis
[0133] Since exosomal lncRNA-PATB1 promotes the occurrence of lymphatic endothelial regeneration, the specific molecular mechanism was further studied. First, by knocking down the expression of hnRNPA1 in pancreatic ductal adenocarcinoma cells, it was found that the expression of lncRNA-PATB1 in pancreatic ductal adenocarcinoma exosomes also decreased significantly, while there was no significant change in lncRNA-PATB1 in pancreatic cancer cells, confirming that hnRNPA1 is involved in mediating the entry of lncRNA-PATB1 into exosomes ( Figure 7 AB). Exosome uptake experiments confirmed that exosomal lncRNA-PATB1 can be specifically taken up by lymphatic endothelial cells ( Figure 7 CE). qRT-PCR confirmed that exosomal lncRNA-PATB1 promoted the expression of SOX18, a key protein of lymphatic phenotype, in lymphatic endothelial cells ( Figure 7 FG). Further ChIRP experiments confirmed that exosome-mediated lncRNA-PATB1 directly binds to the promoter region of SOX18 ( Figure 7 HI). Therefore, pancreatic ductal adenocarcinoma activates the transcription of SOX18 in lymphatic endothelial cells by secreting exosomal lncRNA-PATB1, thereby promoting lymphatic endothelial regeneration and lymphatic metastasis.
[0134] 9. Exosomal lncRNA-PATB1 is positively correlated with lymph node metastasis in patients with pancreatic ductal adenocarcinoma
[0135] Exosomes are important detection targets for liquid biopsy. By detecting the biological molecules they carry, they can be used for the diagnosis of various tumors. Therefore, in order to further explore whether exosome lncRNA-PATB1 can be used as a molecular marker for pancreatic ductal adenocarcinoma metastasis, the present invention isolated exosomes from 92 pancreatic ductal adenocarcinoma patients and 92 normal human serum specimens and detected the expression of lncRNA-PATB1. The results showed that the expression of lncRNA-PATB1 in the exosomes of pancreatic ductal adenocarcinoma patients was higher than that in the exosomes of normal people ( Figure 8 A). Further analysis of the clinicopathological characteristics of patients with pancreatic ductal adenocarcinoma revealed that the expression of exosomal lncRNA-PATB1 was associated with lymph node metastasis and clinical stage (Table 6). qRT-PCR assay confirmed that the expression of lncRNA-PATB1 in exosomes of patients with pancreatic ductal adenocarcinoma with positive lymph node metastasis or advanced clinical stage was higher than that of patients with pancreatic ductal adenocarcinoma with negative lymph node metastasis or early clinical stage ( Figure 8 BC).
[0136] Table 6 Relationship between the expression of exosomal LncRNA-PATB1 and clinical characteristics of patients with pancreatic ductal adenocarcinoma
[0137]
[0138] Note: a Chi-square test, *p<0.05, **p<0.01.
[0139] 10. Overexpression of exosomal lncRNA-PATB1 indicates poor prognosis in patients with pancreatic ductal adenocarcinoma
[0140] The present invention further followed up 92 patients with pancreatic ductal adenocarcinoma, and the results of survival analysis suggested that high expression of lncRNA-PATB1 in exosomes of patients with pancreatic ductal adenocarcinoma was associated with shorter overall survival and disease-free survival of patients with pancreatic ductal adenocarcinoma ( Fig. 9 AB). Further univariate and multivariate analyses confirmed that exosomal lncRNA-PATB1 was an independent prognostic factor for overall survival in patients with pancreatic ductal adenocarcinoma (Table 7). More importantly, the expression of exosomal lncRNA-PATB1 was negatively correlated with the overall survival of patients with pancreatic ductal adenocarcinoma with lymph node metastasis ( Fig. 9 C), further suggesting that the expression of exosomal lncRNA-PATB1 can indicate the prognosis of patients with lymph node metastasis.
[0141] Table 7 Univariate and multivariate analysis of factors affecting overall survival (OS) in patients with pancreatic ductal adenocarcinoma (n = 92)
[0142]
[0143]
[0144] Note: *p<0.05, **p<0.01.
[0145] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of an inhibitor of lncRNA-PATB1 in preparing a product for treating pancreatic ductal adenocarcinoma, wherein the inhibitor is siRNA; the RNA sequence of the lncRNA-PATB1 is shown in SEQ ID NO:
1.
2. Use of a reagent for detecting the expression level of lncRNA-PATB1 in the preparation of a kit for diagnosing pancreatic ductal adenocarcinoma metastasis or pancreatic ductal adenocarcinoma prognosis; the RNA sequence of the lncRNA-PATB1 is shown in SEQ ID NO:
1.
3. The use according to claim 2, characterized in that: The reagent is selected from an oligonucleotide probe that specifically recognizes the lncRNA-PATB1 gene.
4. A drug for treating pancreatic ductal adenocarcinoma, characterized in that: The drug comprises an inhibitor that reduces the expression level of lncRNA-PATB1; the RNA sequence of the lncRNA-PATB1 is shown in SEQ ID NO: 1, and the inhibitor is siRNA.
